Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05822362 · ClinicalTrials.gov registry record · Phase 2

CBD for Individuals at Risk for Alzheimer's Disease

A Phase 2 study of Mild Cognitive Impairment, sponsored by University of Colorado, Denver.

Recruiting
Registry status
Phase 2
Development phase
236
Enrollment target
1
Study location

NCT05822362 is a Phase 2 study of Mild Cognitive Impairment that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 236 participants, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05822362, a Phase 2 study of Mild Cognitive Impairment, is actively recruiting participants, sponsored by University of Colorado, Denver.

RECRUITING
Registry status
Phase 2
Development phase
236 participants
Enrollment target
1
Study location

Study Summary

This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.

Conditions Studied

Mild Cognitive Impairment

Interventions

  • OTHER Placebo
  • DRUG Cannabidiol

Study Locations (1)

Colorado

  • University of Colorado - Anschutz Medical Campus - Aurora

Trial Details

FieldValue
Enrollment Target 236 participants
Start Date 2024-01-19
Est. Completion 2029-04
Phase Phase 2

Sponsor

University of Colorado, Denver

1,283 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05822362

The ClinicalTrials.gov registry entry for NCT05822362 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (81% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05822362 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT05822362 about?

NCT05822362 is a clinical study titled "CBD for Individuals at Risk for Alzheimer's Disease". This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.

What is the current status of trial NCT05822362?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 236 participants. The study started on 2024-01-19. Estimated completion is 2029-04.

What conditions does trial NCT05822362 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment.

What interventions are being tested in trial NCT05822362?

The interventions under investigation include: Placebo (OTHER), Cannabidiol (DRUG).

Who is sponsoring clinical trial NCT05822362?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05822362 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mild Cognitive Impairment

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.